Related Experiment Video

Updated: Aug 16, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells

Gerald F Davies1, William J Roesler, Bernhard H J Juurlink

  • 1Department of Anatomy, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Leukemia & Lymphoma
|August 9, 2005
PubMed

Insights

Troglitazone (TRG) overcomes doxorubicin (DOX) resistance in human leukemia cells by downregulating glyoxalase 1 (GLO1). TRG may offer a novel adjunct therapy for leukemia treatment, impacting cell cycle and genomic stability.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Doxorubicin (DOX) resistance in human myeloid leukemia cells is linked to elevated glyoxalase 1 (GLO1) expression.
  • Troglitazone (TRG), an anti-diabetic drug, has previously demonstrated GLO1 gene expression downregulation.
  • TRG is investigated as a potential adjunct therapy to overcome DOX resistance.

Purpose of the Study:

  • To evaluate the efficacy of Troglitazone (TRG) in overcoming doxorubicin (DOX) resistance in K562 human leukemia cells.
  • To investigate the molecular mechanisms underlying TRG's effect on DOX-resistant leukemia cells, focusing on histone modifications and cell cycle regulation.

Main Methods:

  • Treatment of DOX-resistant K562 leukemia cells with TRG.
  • Analysis of GLO1 gene expression levels.
  • Assessment of histone H3:H2B ratios.
  • Detection of phosphorylated H3 in treated cells.

Main Results:

  • TRG treatment successfully overcame DOX resistance in K562 leukemia cells.
  • Higher TRG doses altered histone H3:H2B ratios, with distinct changes in sensitive versus resistant cell lines.
  • Phosphorylated H3 was observed in DOX-resistant cells treated with TRG, but not in DOX-sensitive cells.

Conclusions:

  • TRG demonstrates potential as an adjunct therapy to circumvent doxorubicin resistance in K562 leukemia.
  • TRG's mechanism may involve interference with cell cycle progression and induction of genomic instability in resistant cells.
  • Further research into TRG's effects on histone modifications and cell cycle is warranted for leukemia treatment strategies.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...